No information is available on the clinical use of apremilast during breastfeeding. Although it is not contraindicated, international guidelines recommend avoiding apremilast during breastfeeding.[1-3] An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol 2018;59:86-100. [PubMed: 28543445]
2.
Puchner A, Grochenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation: A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr 2019;131:29-44. [PMC free article: PMC6342891] [PubMed: 30643992]
3.
Belinchón I, Velasco M, Ara-Martín M, et al. [Management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding: A consensus statement]. Actas Dermosifiliogr (Engl Ed) 2021;112:225-41. [PubMed: 33065101]
Substance Identification
Substance Name
Apremilast
CAS Registry Number
608141-41-9
Drug Class
Breastfeeding
Lactation
Milk, Human
Analgesics
Antirheumatic Agents
Enzyme Inhibitors
Phosphodiesterase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
